Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | PTGIR | P43119 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975397 | 1.00 | L3MBTL1 (0.39) | L3MBTL1MAPTLMNAMAPK14SIGMAR1 | |
| SCHEMBL19975382 | 1.00 | L3MBTL1 (0.39) | L3MBTL1MAPTLMNAMAPK14SIGMAR1 | |
| SCHEMBL19974799 | 0.87 | SMN1; SMN2 (0.35) | L3MBTL1SIGMAR1PTGIROPRD1OPRK1 | |
| SCHEMBL19974871 | 0.87 | MEN1 (0.39) | L3MBTL1PTGIRCNR1CYP2C19ALDH1A1 | |
| SCHEMBL19975130 | 0.85 | HPGD (0.42) | L3MBTL1MAPTLMNAPTGIRALDH1A1 | |
| SCHEMBL21176277 | 0.84 | PTGIR (0.41) | SIGMAR1PTGIRCYP2C19 | |
| SCHEMBL19975377 | 0.81 | HPGD (0.50) | L3MBTL1MAPTLMNAALDH1A1GAA | |
| SCHEMBL19974932 | 0.81 | L3MBTL1 (0.38) | L3MBTL1MAPTLMNAALDH1A1GAA | |
| SCHEMBL19975208 | 0.80 | EPHX1 (0.43) | L3MBTL1OPRK1ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL19975136 | 0.80 | EPHX1 (0.40) | L3MBTL1PTGIROPRK1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | L3MBTL1 1238/4885MAPT 4561/4885LMNA 1909/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | L3MBTL1 1885/4885MAPT 4673/4885LMNA 2058/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | L3MBTL1 1238/4885MAPT 4561/4885LMNA 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.